Co-formulated favezelimab plus pembrolizumab versus standard-of-care in previously treated, PD-L1-positive metastatic colorectal cancer: The phase 3, randomized KEYFORM-007 study Meeting Abstract
| Authors: | Segal, N. H.; Passhak, M.; Köse, F.; Kubala, E.; Elez, E.; Kawakami, H.; Guren, M. G.; Jonker, D. J.; Xu, R. H.; Riera, J.; Tortora, G.; Siena, S.; Yeh, Y. M.; Yusof, M. M.; Shiu, K. K.; Starling, N.; Peng, X.; Fogelman, D. R.; Adelberg, D. E.; Kim, T. W. |
| Abstract Title: | Co-formulated favezelimab plus pembrolizumab versus standard-of-care in previously treated, PD-L1-positive metastatic colorectal cancer: The phase 3, randomized KEYFORM-007 study |
| Meeting Title: | 2025 ASCO Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2025 Jan 23-25 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-02-01 |
| DOI: | 10.1200/JCO.2025.43.4_suppl.LBA248 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl plus with full text |
| DOI/URL: | |
| Notes: | Meeting abstract: LBA248 -- Source: CINAHL Plus with Full Text |
